BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Xun YH, Shi JP, Li CQ, Li D, Shi WZ, Pan QC, Guo JC, Zang GQ. Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure. Mol Med Rep 2014;9:1559-68. [PMID: 24573151 DOI: 10.3892/mmr.2014.1983] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
2 Zhao B, Zhang HY, Xie GJ, Liu HM, Chen Q, Li RF, You JP, Yang S, Mao Q, Zhang XQ. Evaluation of the efficacy of steroid therapy on acute liver failure. Exp Ther Med 2016;12:3121-9. [PMID: 27882127 DOI: 10.3892/etm.2016.3720] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, Xu BY, Mao Q. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46-53. [PMID: 20973887 DOI: 10.1111/j.1872-034x.2010.00740.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
5 Chan HL, Wong VW. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 540-63. [DOI: 10.1016/b978-1-4377-0881-3.00030-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol. 2014;20:16037-16052. [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
7 Qi ZX, Wang LY, Fan YC, Zhang JJ, Li T, Wang K. Increased peripheral RORα and RORγt mRNA expression is associated with acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2012;19:811-822. [PMID: 23043388 DOI: 10.1111/j.1365-2893.2012.01603.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
8 Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother 2015;59:3168-73. [PMID: 25779569 DOI: 10.1128/AAC.00261-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
10 Zhou TC, Liu FW, Fan JH, Zhang SH, Lv SQ, Yu ZY, Zhang YM, Zhang L, Wei J. The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years. Infect Genet Evol 2021;89:104706. [PMID: 33418145 DOI: 10.1016/j.meegid.2021.104706] [Reference Citation Analysis]
11 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
12 Zhou RR, Liu HB, Peng JP, Huang Y, Li N, Xiao MF, Wang H, Fan XG. High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury. Exp Mol Pathol. 2012;93:213-219. [PMID: 22609241 DOI: 10.1016/j.yexmp.2012.05.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
13 Mao Q, Zhang HY, You JP, Zhang XQ. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid. Virol J 2012;9:136. [PMID: 22828242 DOI: 10.1186/1743-422X-9-136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
14 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 949] [Article Influence: 179.3] [Reference Citation Analysis]
15 Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci 2019;64:2563-9. [PMID: 30835025 DOI: 10.1007/s10620-019-05571-0] [Reference Citation Analysis]
16 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
17 Zhe-Bin W, Ke W, Mo ZS, Zhen X, Yu-Bao Z, Ying Y, Zhi-Liang G. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure. Clin Res Hepatol Gastroenterol 2020;:101505. [PMID: 32896504 DOI: 10.1016/j.clinre.2020.07.010] [Reference Citation Analysis]
18 Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, Chan HY, Wong VW. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014;39:197-208. [PMID: 24261924 DOI: 10.1111/apt.12559] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
19 Chen YC, Hsu CW, Chang MY, Yeh CT. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013;6:349. [PMID: 24004574 DOI: 10.1186/1756-0500-6-349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
21 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan H, Sung JJ, Chan HL. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2011;54:236-42. [DOI: 10.1016/j.jhep.2010.06.043] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 8.3] [Reference Citation Analysis]
22 Tan W, Xia J, Dan Y, Li M, Lin S, Pan X, Wang H, Tang Y, Liu N, Tan S, Liu M, He W, Zhang W, Mao Q, Wang Y, Deng G. Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure. Gut 2018;67:757-66. [PMID: 28130311 DOI: 10.1136/gutjnl-2016-313035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
23 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
24 Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol 2013;3:301-12. [PMID: 25755518 DOI: 10.1016/j.jceh.2013.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
25 Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017;51:539-47. [PMID: 28067752 DOI: 10.1097/MCG.0000000000000675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bestas R, Yalcin K. Clinical and Virological Features of Acute Hepatic Exacerbations in Patients With Chronic Hepatitis B Virus Infection. Cureus 2021;13:e15937. [PMID: 34194888 DOI: 10.7759/cureus.15937] [Reference Citation Analysis]
27 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
28 Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-143. [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
29 Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014;60:1127-1134. [PMID: 24583247 DOI: 10.1016/j.jhep.2014.02.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
30 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 5.9] [Reference Citation Analysis]
31 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chang PE, Goh GB, Tan CK. Low serum albumin and advanced age predict early mortality in Asian patients with extreme elevations of serum aminotransferase. J Dig Dis. 2016;17:193-201. [PMID: 26879902 DOI: 10.1111/1751-2980.12323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Iregbu KC, Nwajiobi-Princewill PI. Viral Load Pattern Among Hepatitis B Surface Antigen-positive Patients: Laboratory Perspective and Implications for Therapy. Ann Med Health Sci Res 2016;6:95-9. [PMID: 27213092 DOI: 10.4103/2141-9248.181835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Gao FY, Liu Y, Li XS, Ye XQ, Sun L, Geng MF, Wang R, Liu HM, Zhou XB, Gu LL, Liu YM, Wan G, Wang XB. Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World J Gastroenterol. 2015;21:8373-8381. [PMID: 26217089 DOI: 10.3748/wjg.v21.i27.8373] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
35 Palta R, McClune A, Esrason K. Hodgkin’s lymphoma coexisting with liver failure secondary to acute on chronic hepatitis B. World J Clin Cases. 2013;1:37-40. [PMID: 24303460 DOI: 10.12998/wjcc.v1.i1.37] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wong GL. Who will have the best response to entecavir? J Gastroenterol Hepatol 2013;28:5-7. [DOI: 10.1111/jgh.12009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
37 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
38 Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol 2017;8:e104. [PMID: 28662023 DOI: 10.1038/ctg.2017.29] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
39 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
40 Chen L, Zheng C, Lin M, Huang Z, Chen R, Li Q, Li Q, Chen P. Distinct quasispecies characteristics and positive selection within precore/core gene in hepatitis B virus HBV associated acute-on-chronic liver failure: Viral quasispecies in liver failure. J Gastroenterol Hepatol 2013;28:1040-6. [DOI: 10.1111/jgh.12109] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
41 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Xu BY, Tan WT, Tan S, Dan YJ, Luo XL, Deng GH. Serum testosterone levels and androgen receptor CAG polymorphism correlate with hepatitis B virus (HBV)-related acute liver failure in male HBV carriers. PLoS One 2013;8:e84213. [PMID: 24391916 DOI: 10.1371/journal.pone.0084213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 37.0] [Reference Citation Analysis]
44 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
45 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]